CASI Pharmaceuticals, Inc., a U.S.-based biopharmaceutical company providing pharmaceutical products and therapeutics to patients in China and throughout the world, has entered into framework agreements to build a manufacturing site strategically located in the Wuxi Huishan Economic Development Zone in Jiangsu Province, China.
The Wuxi development zone is a leading science and technology innovation center in the region.
The facility will be designed and constructed based on global cGMP requirements and is expected to have capacity for large scale production. It will be a key asset supporting CASI’s growth and commercialization plans with further agreements to be finalized and site construction to begin in mid-2019, according to the company.
“The facility will be a core component of our long-term growth strategy as it will give us significantly greater capacity in order to meet the company’s commercial needs, and also will allow us greater control over quality, cost of goods, and to accelerate production schedules,” Wei-Wu He, Ph.D., CASI’s executive chairman, said in a statement.
(Source: CASI Pharmaceuticals, Inc.)